Portola Pharmaceuticals has entered into a clinical collaboration with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo’s Factor Xa inhibitor, in Japan. Portola is developing andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, for patients treated with a direct or indirect Factor Xa inhibitor when reversal of anticoagulation is needed, such as for life-threatening or uncontrolled bleeding or emergency surgery and urgen...